Urologic Oncology Program

The Urologic Oncology Program at the Henry Ford Cancer Institute includes investigators from the Vattikuti Urology Institute and the Department of Surgery. Our research programs are built on close interactions between basic scientists and practicing clinicians. The programs benefit from the prostate tissue biorepository, which includes over 10,000 vials of cancerous and adjacent normal prostate tissue specimens. We use the Robosurge database. Robosurge is a dedicated database of over 5,000 robotic-assisted prostatectomy cases performed at our institution since 2001. This database contains patients' demographics, pre-operative health status, disease characteristics per biopsy and surgical specimen, and surgical parameters.

The clinical program offers the most advanced treatments for:


  • Improving robotic surgical techniques for kidney cancer
  • Identification and utilization of biomarkers and genes for the diagnosis, prognosis and treatment of kidney and prostate cancer
  • Improving robotic surgical techniques for bladder cancer
  • Identification and utilization of biomarkers and genes for the diagnosis, prognosis and treatment of bladder cancer
  • Discovery of molecular markers for early detection and prognosis of prostate cancer, and on novel targets for prostate cancer treatment
  • Identify RNA-based markers that can detect prostate cancer earlier and more accurately than currently possible
  • Determine whether markers of early disease differ between African American (AA) and European American (EA) men
  • Identify small molecules that can selectively disrupt calmodulin interaction with the androgen receptor and render the androgen receptor susceptible to proteolytic breakdown
  • Prostate cancer outcome prediction in African American men
  • Identification of markers of metastatic prostate cancer is to identify patients with organ-confined disease vs. metastatic disease at the time of radical prostatectomy (RP), based on long-term follow-up after RP, and then to analyze the primary tumors to identify molecular changes that distinguish between these outcome groups
  • Use of 5-lipoxygenase and the proteins involved in its metabolite-induced signaling pathway as novel therapeutic targets for the treatment of prostate cancer
  • Approaches to identify androgen receptor-interacting telomeric proteins that can be targeted for the treatment of prostate cancer
  • Development and application of statistical methods for observational and correlated data, and quantitative synthesis of medical evidence
  • Understanding the molecular mechanisms of chemotherapy-resistance and applying this knowledge to the care of patients with metastatic prostate cancer
  • Use of oleanolic acid and ursolic acid (naturally occurring triterpenoids that have been used in traditional medicine as antibacterial, anti-inflammatory, and anti-cancer agents) to treat prostate cancer

See member profiles for comprehensive cancer research interests

Leader and clinical co-leader

  • Reddy, Prem-Veer, Ph.D.
  • Hwang, Clara, M.D.

Research members

  • Barrack, Evelyn, Ph.D.
  • Diaz, Mireya, Ph.D.
  • Gautam, Subhash, Ph.D.
  • Ghosh, Jagadananda, Ph.D.
  • Kim, Sahn-Ho, Ph.D.
  • Neslund-Dudas, Christine, Ph.D.
  • Rybicki, Ben, Ph.D.

Clinical members

  • Gupta, Nilesh, M.D.
  • Menon, Mani, M.D.
  • Park, Hakim, M.D.
  • Peabody, Jim, M.D.
  • Rogers, Craig, M.D.